X-Linked Intellectual Disability CRISPR Models for Drug Discovery

X-linked intellectual disability (XLID) represents a significant fraction of inherited intellectual disability, with an estimated prevalence of 1-2 per 1,000 males worldwide (WHO, 2023). Over 140 genes on the X chromosome have been associated with XLID, accounting for approximately 10-15% of all intellectual disability cases in males. The condition is characterized by impaired cognitive function, with many patients also presenting with autism spectrum features, seizures, and distinct physical phenotypes. The lifetime burden is substantial, with no curative treatments currently available, driving the need for preclinical models to understand pathophysiology and test therapeutic interventions.

XLID is an ideal model for studying neurodevelopmental disorders due to its genetic heterogeneity and well-defined monogenic subtypes. The availability of large-scale sequencing data from initiatives like the NCBI ClinVar database and the XLID consortium provides a rich resource for genotype-phenotype correlations. Key open questions include the molecular mechanisms linking synaptic dysfunction to cognitive impairment, the role of X-chromosome inactivation in female carriers, and the identification of common pathways across different XLID genes. Gene-edited cell models enable precise dissection of these mechanisms in human neuronal contexts.

XLID genes converge on several key pathways essential for synaptic plasticity and neuronal development:

1. Rho GTPase signaling: Regulates dendritic spine morphology and synaptic structure.

• • Key genes: ARHGEF6, OPHN1, PAK3
• • Disruption leads to abnormal spine density and impaired long-term potentiation.

2. Synaptic scaffolding and adhesion: Controls synapse formation and function.

• • Key genes: NLGN3, NLGN4, SHANK3, DLG3
• • Mutations impair excitatory/inhibitory balance.

3. Chromatin remodeling and transcription: Regulates gene expression programs for neuronal maturation.

• • Key genes: MECP2, ATRX, KDM5C
• • Altered histone methylation and DNA methylation affect synaptic gene expression.

4. Ubiquitin-proteasome system: Controls protein turnover at synapses.

• • Key genes: HUWE1, UBE2A
• • Impaired degradation leads to accumulation of synaptic proteins.

Data from ClinVar (NCBI, 2024) and COSMIC (Sanger Institute, 2024).

Key signaling networks disrupted in XLID include:

• • RhoA/ROCK pathway: Mutations in ARHGEF6 and OPHN1 lead to reduced RhoA activation, resulting in immature dendritic spines and impaired synaptic plasticity.
• • mTOR signaling: FMRP loss leads to dysregulated translation of mTOR pathway components, causing exaggerated protein synthesis and synaptic dysfunction.
• • Wnt/β-catenin signaling: Mutations in KDM5C and other chromatin remodelers alter Wnt target gene expression, affecting neuronal differentiation.
• • MAPK/ERK pathway: Implicated in synaptic plasticity; mutations in PAK3 disrupt downstream signaling to the cytoskeleton.
• • Calcium signaling: NLGN3 mutations alter calcium influx through NMDA receptors, disrupting activity-dependent gene expression.

Organoid models, particularly cerebral organoids derived from patient iPSCs, recapitulate early neurodevelopmental stages and allow study of XLID gene function in a 3D context with multiple cell types.

• • Fmr1 knockout mouse: Most widely used model for Fragile X syndrome; exhibits impaired synaptic plasticity, increased mGluR signaling, and behavioral deficits.
• • Mecp2 knockout mouse: Models Rett syndrome; shows progressive neurological decline, motor deficits, and reduced lifespan.
• • Arhgef6 knockout mouse: Displays abnormal dendritic spine morphology and impaired spatial learning.
• • Shank3 knockout mouse: Shows autism-like behaviors, reduced social interaction, and altered glutamatergic transmission.
• • Nlgn3 R451C knock-in mouse: Exhibits increased inhibitory synaptic transmission and impaired social behavior.

CRISPR/Cas9 gene editing enables the generation of isogenic cell lines with precise mutations in XLID genes. For example, TP53-/- and KRAS G12D models are commonly used in cancer research, but for XLID, key models include:

• • FMR1 knockout iPSC lines: Complete loss of FMRP expression, recapitulating Fragile X syndrome.
• • MECP2 R168X knock-in iPSC lines: Introduces a common nonsense mutation found in Rett syndrome.
• • SHANK3 homozygous deletion iPSC lines: Models Phelan-McDermid syndrome.
• • NLGN3 R451C knock-in iPSC lines: Models a gain-of-function mutation associated with autism.

These commercially available, sequence-verified models accelerate research by providing reproducible, isogenic controls that eliminate genetic background variability. They are ideal for drug screening, target validation, and mechanistic studies.

CRISPR knockout and knock-in lines are used to validate the functional impact of XLID genes. For example:

• • FMR1 knockout iPSC-derived neurons show reduced synaptic protein synthesis and altered mGluR signaling, confirming the role of FMRP in translational regulation.
• • MECP2 mutant iPSC lines exhibit aberrant gene expression profiles, identifying downstream targets such as BDNF and DLX5.
• • SHANK3 knockout neurons display reduced dendritic spine density and impaired synaptic transmission, validating its role in synaptic scaffolding.

Isogenic pairs (mutant vs. wild-type) enable high-throughput screening for compounds that rescue the disease phenotype. Examples include:

• • Screening for mGluR5 antagonists in FMR1 knockout neurons to identify compounds that reduce exaggerated protein synthesis.
• • Testing IGF-1 analogs in MECP2 mutant neurons to improve synaptic function.
• • Evaluating compounds that enhance SHANK3 expression in deletion models.

Resistance modeling is less relevant for XLID, but gene-edited cells can be used to study compensatory mechanisms.

CRISPR synthetic lethality screens in XLID gene-edited cells can identify genetic interactions and potential therapeutic targets. For example:

• • Screening for genes whose knockout exacerbates or rescues the FMR1 loss-of-function phenotype.
• • Identifying modifiers of MECP2 mutation severity using genome-wide CRISPR libraries.
• • Discovering biomarkers of neuronal dysfunction, such as altered calcium signaling or synaptic protein levels.